L. Michael Glodé, MD, FACP, presented “TMPRSS2, ACE 2, and the Potential Role of 5ARIs and GNRH Analogues in Inhibiting COVID-19 Infection” for the Grand Rounds in Urology audience in May, 2020.
How to cite: Glodé, L. Michael. “TMPRSS2, ACE 2, and the Potential Role of 5ARIs and GNRH Analogues in Inhibiting COVID-19 Infection” May, 2020. Accessed Nov 2024. https://grandroundsinurology.com/tmprss2-ace-2-and-the-potential-role-of-5aris-and-gnrh-analogues-in-inhibiting-covid-19-infection/
TMPRSS2, ACE 2, and the Potential Role of 5ARIs and GNRH Analogues in Inhibiting COVID-19 Infection – Summary:
L. Michael Glodé, MD, FACP, Professor Emeritus at the University of Colorado Cancer Center and a medical oncologist at the Shaw Regional Cancer Center in Edwards, Colorado, discusses the mechanism of action of the TMPRSS2 and ACE2 pathways, and their relationship to the host-cell entry of COVID-19. He goes on to discuss a clinical trial using the serine protease inhibitor Camostat, noting how 5ARIs and GNRH analogues could act as a target for prevention and possible treatment of COVID-19. He also discusses the results of an Italian observational study which demonstrated how prostate cancer patients receiving ADT appear to be partially protected from COVID-19 infection.
For other urology-focused information on the COVID-19 pandemic, visit our resource page.
